Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 96 | 2023 | 545 | 19.790 |
Why?
|
Brain Ischemia | 23 | 2018 | 136 | 4.790 |
Why?
|
Ischemic Attack, Transient | 16 | 2022 | 46 | 4.760 |
Why?
|
Women's Health | 13 | 2014 | 226 | 3.000 |
Why?
|
Pregnancy Complications, Cardiovascular | 10 | 2018 | 21 | 2.370 |
Why?
|
Sex Characteristics | 11 | 2022 | 167 | 2.350 |
Why?
|
Secondary Prevention | 12 | 2020 | 59 | 2.210 |
Why?
|
Humans | 129 | 2023 | 29093 | 2.000 |
Why?
|
Migraine Disorders | 6 | 2014 | 58 | 1.960 |
Why?
|
Female | 95 | 2022 | 18164 | 1.930 |
Why?
|
Patient Readmission | 5 | 2021 | 105 | 1.810 |
Why?
|
Risk Factors | 44 | 2022 | 3531 | 1.670 |
Why?
|
Estrogen Replacement Therapy | 8 | 2014 | 182 | 1.600 |
Why?
|
Pregnancy Complications | 6 | 2017 | 80 | 1.480 |
Why?
|
Patient Discharge | 14 | 2022 | 168 | 1.460 |
Why?
|
Pregnancy | 21 | 2018 | 815 | 1.330 |
Why?
|
Telemedicine | 3 | 2023 | 73 | 1.270 |
Why?
|
Medicare | 5 | 2022 | 186 | 1.270 |
Why?
|
Aged | 48 | 2022 | 9487 | 1.170 |
Why?
|
Subacute Care | 5 | 2022 | 11 | 1.170 |
Why?
|
United States | 30 | 2022 | 3630 | 1.060 |
Why?
|
Male | 52 | 2023 | 17807 | 1.010 |
Why?
|
Pre-Eclampsia | 2 | 2018 | 53 | 0.940 |
Why?
|
Middle Aged | 45 | 2020 | 10829 | 0.900 |
Why?
|
Patient-Centered Care | 3 | 2018 | 68 | 0.890 |
Why?
|
Anticoagulants | 7 | 2018 | 120 | 0.840 |
Why?
|
Fee-for-Service Plans | 1 | 2021 | 10 | 0.830 |
Why?
|
Hospitals | 7 | 2019 | 89 | 0.790 |
Why?
|
Hypertension, Pregnancy-Induced | 2 | 2018 | 10 | 0.780 |
Why?
|
Postpartum Period | 3 | 2018 | 29 | 0.770 |
Why?
|
Venous Thrombosis | 3 | 2018 | 48 | 0.730 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2017 | 126 | 0.720 |
Why?
|
Primary Prevention | 3 | 2014 | 47 | 0.710 |
Why?
|
Vasospasm, Intracranial | 1 | 2019 | 13 | 0.700 |
Why?
|
Cardiovascular Diseases | 8 | 2021 | 1013 | 0.700 |
Why?
|
Vasoconstriction | 1 | 2019 | 40 | 0.700 |
Why?
|
Hypertension | 6 | 2018 | 906 | 0.690 |
Why?
|
Cerebrovascular Disorders | 1 | 2019 | 48 | 0.680 |
Why?
|
Cerebral Hemorrhage | 5 | 2020 | 62 | 0.670 |
Why?
|
Intracranial Thrombosis | 3 | 2014 | 8 | 0.660 |
Why?
|
Research Design | 6 | 2021 | 286 | 0.630 |
Why?
|
Brain Diseases | 1 | 2018 | 40 | 0.620 |
Why?
|
Aged, 80 and over | 19 | 2020 | 3717 | 0.610 |
Why?
|
Thrombolytic Therapy | 1 | 2017 | 59 | 0.610 |
Why?
|
Vascular Diseases | 2 | 2009 | 61 | 0.600 |
Why?
|
Practice Guidelines as Topic | 5 | 2019 | 374 | 0.600 |
Why?
|
Nurse Practitioners | 1 | 2016 | 9 | 0.570 |
Why?
|
Severity of Illness Index | 5 | 2020 | 863 | 0.570 |
Why?
|
Depression | 4 | 2017 | 380 | 0.560 |
Why?
|
Mobility Limitation | 1 | 2017 | 187 | 0.560 |
Why?
|
Menopause | 4 | 2021 | 86 | 0.550 |
Why?
|
Patient Education as Topic | 5 | 2018 | 251 | 0.540 |
Why?
|
Upper Extremity | 1 | 2015 | 52 | 0.520 |
Why?
|
American Heart Association | 7 | 2014 | 84 | 0.520 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 35 | 0.520 |
Why?
|
Tamoxifen | 2 | 2005 | 48 | 0.510 |
Why?
|
Lower Extremity | 1 | 2015 | 93 | 0.500 |
Why?
|
Antidepressive Agents | 2 | 2012 | 70 | 0.500 |
Why?
|
Societies, Medical | 2 | 2019 | 149 | 0.490 |
Why?
|
Guidelines as Topic | 1 | 2014 | 45 | 0.480 |
Why?
|
Registries | 7 | 2017 | 278 | 0.480 |
Why?
|
Aspirin | 6 | 2018 | 61 | 0.460 |
Why?
|
Atrial Fibrillation | 5 | 2017 | 311 | 0.450 |
Why?
|
Neurology | 4 | 2020 | 45 | 0.450 |
Why?
|
Hospitals, Community | 1 | 2012 | 10 | 0.440 |
Why?
|
Treatment Outcome | 14 | 2021 | 3099 | 0.430 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 61 | 0.420 |
Why?
|
Homocysteine | 2 | 2020 | 15 | 0.420 |
Why?
|
Hyperlipidemias | 3 | 2014 | 50 | 0.420 |
Why?
|
Incidence | 10 | 2018 | 1119 | 0.410 |
Why?
|
Quality of Life | 3 | 2017 | 816 | 0.410 |
Why?
|
Continuity of Patient Care | 1 | 2012 | 64 | 0.410 |
Why?
|
Antihypertensive Agents | 4 | 2018 | 339 | 0.400 |
Why?
|
Depressive Disorder | 1 | 2011 | 74 | 0.400 |
Why?
|
Cerebral Arteries | 2 | 2014 | 18 | 0.390 |
Why?
|
Pulsatile Flow | 3 | 2015 | 25 | 0.390 |
Why?
|
Platelet Aggregation Inhibitors | 5 | 2017 | 82 | 0.390 |
Why?
|
Premenstrual Syndrome | 1 | 2010 | 3 | 0.390 |
Why?
|
Prevalence | 6 | 2021 | 896 | 0.380 |
Why?
|
Risk | 2 | 2008 | 289 | 0.370 |
Why?
|
Aftercare | 4 | 2022 | 28 | 0.370 |
Why?
|
Models, Statistical | 1 | 2011 | 163 | 0.360 |
Why?
|
Time Factors | 12 | 2018 | 2001 | 0.360 |
Why?
|
Prognosis | 7 | 2018 | 1362 | 0.350 |
Why?
|
Appointments and Schedules | 1 | 2009 | 16 | 0.350 |
Why?
|
Life Change Events | 1 | 2009 | 21 | 0.350 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2011 | 464 | 0.340 |
Why?
|
Puerperal Disorders | 3 | 2017 | 6 | 0.340 |
Why?
|
Adult | 16 | 2018 | 8420 | 0.330 |
Why?
|
Headache Disorders, Primary | 1 | 2008 | 3 | 0.320 |
Why?
|
Risk Assessment | 12 | 2020 | 1305 | 0.320 |
Why?
|
Longitudinal Studies | 9 | 2017 | 720 | 0.320 |
Why?
|
North Carolina | 7 | 2021 | 1423 | 0.320 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 298 | 0.320 |
Why?
|
Healthcare Disparities | 4 | 2017 | 153 | 0.310 |
Why?
|
Hospitalization | 5 | 2017 | 417 | 0.310 |
Why?
|
Thrombectomy | 2 | 2018 | 58 | 0.310 |
Why?
|
Case-Control Studies | 5 | 2014 | 859 | 0.310 |
Why?
|
Follow-Up Studies | 7 | 2018 | 2108 | 0.300 |
Why?
|
Retrospective Studies | 7 | 2020 | 3111 | 0.290 |
Why?
|
Medication Adherence | 4 | 2018 | 144 | 0.290 |
Why?
|
Quality of Health Care | 2 | 2020 | 134 | 0.280 |
Why?
|
Somatoform Disorders | 1 | 2005 | 7 | 0.280 |
Why?
|
Magnetic Resonance Imaging | 6 | 2019 | 1218 | 0.280 |
Why?
|
Intracranial Hemorrhages | 2 | 2017 | 31 | 0.270 |
Why?
|
Disability Evaluation | 4 | 2017 | 211 | 0.270 |
Why?
|
Electroencephalography | 1 | 2005 | 71 | 0.270 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2005 | 11 | 0.270 |
Why?
|
Seizures | 1 | 2005 | 61 | 0.270 |
Why?
|
Recovery of Function | 4 | 2017 | 190 | 0.270 |
Why?
|
Internship and Residency | 1 | 2009 | 283 | 0.260 |
Why?
|
Survivors | 3 | 2023 | 145 | 0.260 |
Why?
|
African Americans | 3 | 2020 | 1373 | 0.260 |
Why?
|
Tetrazoles | 2 | 2015 | 71 | 0.260 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2004 | 29 | 0.250 |
Why?
|
Prospective Studies | 8 | 2017 | 2019 | 0.250 |
Why?
|
Estrogens | 1 | 2005 | 162 | 0.250 |
Why?
|
Economics, Pharmaceutical | 1 | 2004 | 5 | 0.250 |
Why?
|
Age Factors | 6 | 2012 | 1108 | 0.240 |
Why?
|
Anticholesteremic Agents | 1 | 2004 | 36 | 0.240 |
Why?
|
Thrombophilia | 1 | 2003 | 6 | 0.230 |
Why?
|
Contraceptives, Oral, Hormonal | 2 | 2018 | 7 | 0.230 |
Why?
|
Emergency Medical Services | 2 | 2019 | 157 | 0.230 |
Why?
|
Odds Ratio | 6 | 2017 | 447 | 0.230 |
Why?
|
Patient Selection | 3 | 2018 | 257 | 0.230 |
Why?
|
Hemianopsia | 1 | 2023 | 5 | 0.230 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2020 | 17 | 0.220 |
Why?
|
Comorbidity | 4 | 2014 | 540 | 0.220 |
Why?
|
Caregivers | 3 | 2018 | 94 | 0.220 |
Why?
|
Blood Coagulation Tests | 1 | 2002 | 6 | 0.220 |
Why?
|
Blood Coagulation Disorders | 1 | 2002 | 9 | 0.210 |
Why?
|
Ambulatory Care | 1 | 2022 | 96 | 0.210 |
Why?
|
Predictive Value of Tests | 5 | 2017 | 787 | 0.210 |
Why?
|
Skilled Nursing Facilities | 2 | 2021 | 9 | 0.210 |
Why?
|
Breast Neoplasms | 2 | 2005 | 666 | 0.200 |
Why?
|
Mass Screening | 1 | 2003 | 223 | 0.200 |
Why?
|
Endpoint Determination | 1 | 2021 | 19 | 0.200 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2014 | 125 | 0.200 |
Why?
|
Fibrinolytic Agents | 2 | 2011 | 70 | 0.190 |
Why?
|
Hyperhomocysteinemia | 1 | 2020 | 4 | 0.190 |
Why?
|
Disabled Persons | 2 | 2014 | 83 | 0.190 |
Why?
|
Activities of Daily Living | 2 | 2014 | 238 | 0.190 |
Why?
|
Gene Expression | 2 | 2012 | 332 | 0.190 |
Why?
|
Ultrasonography, Doppler, Transcranial | 3 | 2015 | 32 | 0.190 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 481 | 0.190 |
Why?
|
Gene Expression Profiling | 5 | 2014 | 320 | 0.180 |
Why?
|
Health Care Costs | 1 | 2021 | 108 | 0.180 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 66 | 0.180 |
Why?
|
Memory Disorders | 1 | 2020 | 61 | 0.180 |
Why?
|
Sex Factors | 2 | 2020 | 631 | 0.180 |
Why?
|
Linear Models | 3 | 2017 | 426 | 0.180 |
Why?
|
Organizational Policy | 1 | 2019 | 20 | 0.180 |
Why?
|
Clinical Competence | 1 | 2002 | 307 | 0.170 |
Why?
|
Certification | 1 | 2019 | 24 | 0.170 |
Why?
|
Pilot Projects | 2 | 2012 | 469 | 0.170 |
Why?
|
Health Status Indicators | 2 | 2009 | 67 | 0.170 |
Why?
|
Prenatal Care | 2 | 2017 | 46 | 0.170 |
Why?
|
Coronavirus Infections | 1 | 2020 | 72 | 0.170 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 77 | 0.170 |
Why?
|
Data Mining | 1 | 2018 | 7 | 0.170 |
Why?
|
Health Policy | 1 | 2019 | 79 | 0.160 |
Why?
|
Drug Therapy, Combination | 3 | 2014 | 273 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2020 | 142 | 0.160 |
Why?
|
Ethics, Research | 1 | 2018 | 25 | 0.160 |
Why?
|
Memory | 1 | 2020 | 187 | 0.160 |
Why?
|
Tissue Plasminogen Activator | 1 | 2018 | 40 | 0.160 |
Why?
|
Syndrome | 1 | 2018 | 66 | 0.160 |
Why?
|
Delivery, Obstetric | 1 | 2018 | 50 | 0.160 |
Why?
|
Endarterectomy, Carotid | 1 | 2017 | 29 | 0.160 |
Why?
|
Professional Practice | 1 | 2017 | 23 | 0.160 |
Why?
|
Informed Consent | 1 | 2018 | 51 | 0.160 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 29 | 0.160 |
Why?
|
Cardiomyopathies | 1 | 2018 | 48 | 0.160 |
Why?
|
Public Health Practice | 1 | 2017 | 8 | 0.150 |
Why?
|
Electronic Health Records | 1 | 2018 | 118 | 0.150 |
Why?
|
Women's Rights | 1 | 2017 | 3 | 0.150 |
Why?
|
Sex Distribution | 2 | 2014 | 186 | 0.150 |
Why?
|
Chronic Disease | 2 | 2015 | 369 | 0.150 |
Why?
|
Myocardial Ischemia | 1 | 2017 | 83 | 0.150 |
Why?
|
Cohort Studies | 3 | 2011 | 1687 | 0.150 |
Why?
|
Exercise | 1 | 2022 | 591 | 0.150 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 55 | 0.140 |
Why?
|
HIV Infections | 1 | 2021 | 335 | 0.140 |
Why?
|
Brain | 4 | 2023 | 930 | 0.140 |
Why?
|
Health Status | 3 | 2018 | 368 | 0.140 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 207 | 0.140 |
Why?
|
Expert Testimony | 1 | 2015 | 10 | 0.140 |
Why?
|
Diagnosis, Differential | 2 | 2009 | 493 | 0.140 |
Why?
|
Blood Pressure | 3 | 2014 | 804 | 0.140 |
Why?
|
Uric Acid | 1 | 2015 | 24 | 0.140 |
Why?
|
Educational Status | 2 | 2014 | 164 | 0.130 |
Why?
|
Home Care Services | 1 | 2016 | 48 | 0.130 |
Why?
|
Cognition | 2 | 2020 | 526 | 0.130 |
Why?
|
Adolescent | 6 | 2012 | 3254 | 0.130 |
Why?
|
Histoplasmosis | 1 | 2015 | 2 | 0.130 |
Why?
|
Vasculitis | 1 | 2015 | 23 | 0.130 |
Why?
|
Algorithms | 1 | 2018 | 462 | 0.130 |
Why?
|
Coronary Disease | 2 | 2008 | 200 | 0.130 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 159 | 0.130 |
Why?
|
Leukoencephalopathies | 1 | 2014 | 5 | 0.130 |
Why?
|
Basilar Artery | 1 | 2014 | 10 | 0.130 |
Why?
|
Middle Cerebral Artery | 1 | 2014 | 11 | 0.130 |
Why?
|
Life Style | 2 | 2014 | 364 | 0.130 |
Why?
|
Causality | 1 | 2014 | 37 | 0.130 |
Why?
|
Biomedical Research | 2 | 2020 | 153 | 0.130 |
Why?
|
Health Services for the Aged | 1 | 2014 | 25 | 0.130 |
Why?
|
Intracranial Embolism | 1 | 2014 | 13 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 871 | 0.120 |
Why?
|
Leukocytes | 1 | 2014 | 52 | 0.120 |
Why?
|
Risk Adjustment | 1 | 2014 | 27 | 0.120 |
Why?
|
Hypercholesterolemia | 1 | 2014 | 59 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 709 | 0.120 |
Why?
|
Income | 1 | 2014 | 52 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 116 | 0.120 |
Why?
|
Employment | 1 | 2014 | 49 | 0.120 |
Why?
|
Ischemia | 1 | 2014 | 92 | 0.120 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2014 | 113 | 0.110 |
Why?
|
Young Adult | 2 | 2017 | 2402 | 0.110 |
Why?
|
Reperfusion | 1 | 2012 | 17 | 0.110 |
Why?
|
Chromosomes, Human, Y | 1 | 2012 | 2 | 0.110 |
Why?
|
African Continental Ancestry Group | 1 | 2013 | 350 | 0.110 |
Why?
|
Guideline Adherence | 3 | 2020 | 110 | 0.110 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 12 | 0.100 |
Why?
|
Program Evaluation | 1 | 2012 | 175 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2012 | 263 | 0.100 |
Why?
|
Logistic Models | 3 | 2017 | 727 | 0.100 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2012 | 155 | 0.100 |
Why?
|
Aging | 3 | 2021 | 881 | 0.100 |
Why?
|
Tryptamines | 1 | 2010 | 3 | 0.100 |
Why?
|
Naproxen | 1 | 2010 | 8 | 0.100 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 28 | 0.100 |
Why?
|
Obsessive Behavior | 1 | 2010 | 3 | 0.100 |
Why?
|
Menstrual Cycle | 1 | 2010 | 36 | 0.100 |
Why?
|
Factor Analysis, Statistical | 1 | 2010 | 70 | 0.090 |
Why?
|
Cognition Disorders | 2 | 2015 | 390 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2010 | 37 | 0.090 |
Why?
|
Primary Health Care | 1 | 2012 | 178 | 0.090 |
Why?
|
Physical Therapy Modalities | 1 | 2010 | 60 | 0.090 |
Why?
|
Fetus | 1 | 2010 | 78 | 0.090 |
Why?
|
Urban Population | 1 | 2011 | 79 | 0.090 |
Why?
|
Behavior Therapy | 1 | 2010 | 89 | 0.090 |
Why?
|
Hormone Replacement Therapy | 2 | 2015 | 86 | 0.090 |
Why?
|
Neuropsychological Tests | 3 | 2020 | 379 | 0.090 |
Why?
|
Mental Disorders | 1 | 2010 | 103 | 0.090 |
Why?
|
Health Personnel | 1 | 2010 | 111 | 0.090 |
Why?
|
Analgesics | 1 | 2010 | 126 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2009 | 140 | 0.090 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2009 | 89 | 0.090 |
Why?
|
Telephone | 2 | 2019 | 48 | 0.090 |
Why?
|
Rural Population | 1 | 2011 | 246 | 0.090 |
Why?
|
European Continental Ancestry Group | 1 | 2013 | 1131 | 0.090 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 92 | 0.080 |
Why?
|
Psychometrics | 1 | 2009 | 129 | 0.080 |
Why?
|
Contraceptives, Oral | 1 | 2008 | 20 | 0.080 |
Why?
|
Teaching | 1 | 2009 | 55 | 0.080 |
Why?
|
Frail Elderly | 1 | 2009 | 65 | 0.080 |
Why?
|
Regression Analysis | 1 | 2009 | 274 | 0.080 |
Why?
|
Canada | 2 | 2017 | 48 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2008 | 52 | 0.080 |
Why?
|
Patient Compliance | 1 | 2009 | 208 | 0.080 |
Why?
|
Diabetes Complications | 1 | 2008 | 171 | 0.070 |
Why?
|
Dementia | 1 | 2009 | 234 | 0.070 |
Why?
|
Postmenopause | 2 | 2009 | 397 | 0.070 |
Why?
|
Endometriosis | 1 | 2007 | 66 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2009 | 454 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 32 | 0.070 |
Why?
|
Videotape Recording | 1 | 2005 | 12 | 0.070 |
Why?
|
Epilepsy | 1 | 2005 | 59 | 0.060 |
Why?
|
Carotid Arteries | 1 | 2005 | 97 | 0.060 |
Why?
|
Statistics as Topic | 2 | 2015 | 106 | 0.060 |
Why?
|
Atherosclerosis | 2 | 2013 | 693 | 0.060 |
Why?
|
Warfarin | 2 | 2017 | 30 | 0.060 |
Why?
|
Child | 3 | 2021 | 2219 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 391 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2018 | 222 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2015 | 501 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2005 | 223 | 0.060 |
Why?
|
Blindness | 1 | 2023 | 9 | 0.060 |
Why?
|
Embolism | 1 | 2002 | 6 | 0.060 |
Why?
|
Ethnic Groups | 1 | 2005 | 440 | 0.060 |
Why?
|
Vision, Ocular | 1 | 2023 | 30 | 0.060 |
Why?
|
Photic Stimulation | 1 | 2023 | 155 | 0.050 |
Why?
|
Rehabilitation Centers | 1 | 2021 | 6 | 0.050 |
Why?
|
Acute Disease | 1 | 2002 | 239 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2014 | 726 | 0.050 |
Why?
|
Visual Perception | 1 | 2023 | 112 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 1356 | 0.050 |
Why?
|
Inflammation | 2 | 2015 | 507 | 0.050 |
Why?
|
Organ Size | 2 | 2014 | 196 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2002 | 176 | 0.050 |
Why?
|
Body Mass Index | 2 | 2015 | 865 | 0.050 |
Why?
|
Inpatients | 1 | 2021 | 64 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2002 | 150 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 4 | 0.050 |
Why?
|
Viral Load | 1 | 2021 | 64 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2004 | 412 | 0.050 |
Why?
|
Cluster Analysis | 1 | 2021 | 128 | 0.050 |
Why?
|
Hospital Bed Capacity | 1 | 2020 | 5 | 0.050 |
Why?
|
Ethics, Medical | 1 | 2020 | 16 | 0.050 |
Why?
|
Health Care Rationing | 1 | 2020 | 11 | 0.050 |
Why?
|
Postal Service | 1 | 2019 | 6 | 0.050 |
Why?
|
Health Resources | 1 | 2020 | 33 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2020 | 196 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2002 | 366 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2020 | 118 | 0.040 |
Why?
|
Patient Care Team | 2 | 2012 | 124 | 0.040 |
Why?
|
Republic of Korea | 1 | 2018 | 8 | 0.040 |
Why?
|
Pregnancy in Diabetics | 1 | 2017 | 3 | 0.040 |
Why?
|
Preconception Care | 1 | 2017 | 3 | 0.040 |
Why?
|
Postnatal Care | 1 | 2017 | 5 | 0.040 |
Why?
|
Social Behavior | 1 | 2018 | 67 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2020 | 231 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2017 | 28 | 0.040 |
Why?
|
Cost of Illness | 1 | 2018 | 63 | 0.040 |
Why?
|
Diabetes, Gestational | 1 | 2017 | 21 | 0.040 |
Why?
|
Federal Government | 1 | 2017 | 10 | 0.040 |
Why?
|
Disease Management | 1 | 2018 | 114 | 0.040 |
Why?
|
Government Programs | 1 | 2017 | 8 | 0.040 |
Why?
|
International Normalized Ratio | 1 | 2017 | 5 | 0.040 |
Why?
|
Counseling | 1 | 2017 | 85 | 0.040 |
Why?
|
Pyridones | 1 | 2017 | 9 | 0.040 |
Why?
|
Fertility Agents | 1 | 2017 | 1 | 0.040 |
Why?
|
Contraception | 1 | 2017 | 12 | 0.040 |
Why?
|
Infertility | 1 | 2017 | 13 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2017 | 28 | 0.040 |
Why?
|
Diabetic Angiopathies | 1 | 2017 | 137 | 0.040 |
Why?
|
Pyrazoles | 1 | 2017 | 64 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 162 | 0.040 |
Why?
|
Health Services Research | 1 | 2017 | 78 | 0.040 |
Why?
|
Animals | 2 | 2023 | 7297 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 293 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2018 | 208 | 0.030 |
Why?
|
Survival Rate | 1 | 2018 | 795 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2015 | 1 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2015 | 24 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2017 | 637 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 326 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2015 | 101 | 0.030 |
Why?
|
Erythroblasts | 1 | 2014 | 1 | 0.030 |
Why?
|
Megakaryocytes | 1 | 2014 | 4 | 0.030 |
Why?
|
Vascular Resistance | 1 | 2014 | 28 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2014 | 35 | 0.030 |
Why?
|
Work | 1 | 2014 | 7 | 0.030 |
Why?
|
Retirement | 1 | 2014 | 11 | 0.030 |
Why?
|
Sample Size | 1 | 2014 | 37 | 0.030 |
Why?
|
Models, Organizational | 1 | 2014 | 17 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 350 | 0.030 |
Why?
|
Neutrophils | 1 | 2014 | 102 | 0.030 |
Why?
|
Heart Diseases | 1 | 2014 | 97 | 0.030 |
Why?
|
Age Distribution | 1 | 2013 | 198 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 172 | 0.030 |
Why?
|
Monocytes | 1 | 2014 | 119 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 532 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2013 | 249 | 0.030 |
Why?
|
Specialties, Nursing | 1 | 2012 | 1 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2013 | 181 | 0.030 |
Why?
|
alpha-Galactosidase | 1 | 2011 | 3 | 0.030 |
Why?
|
Ticlopidine | 1 | 2011 | 17 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2011 | 72 | 0.030 |
Why?
|
RNA | 1 | 2011 | 88 | 0.020 |
Why?
|
Up-Regulation | 1 | 2011 | 183 | 0.020 |
Why?
|
Social Class | 1 | 2011 | 78 | 0.020 |
Why?
|
Advisory Committees | 1 | 2010 | 32 | 0.020 |
Why?
|
Emergencies | 1 | 2010 | 45 | 0.020 |
Why?
|
Brain Injuries | 1 | 2010 | 94 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 129 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 246 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 641 | 0.020 |
Why?
|
Reference Values | 1 | 2007 | 224 | 0.020 |
Why?
|
Headache | 1 | 2007 | 74 | 0.020 |
Why?
|
Continental Population Groups | 1 | 2007 | 221 | 0.020 |
Why?
|
Heart Failure | 1 | 2011 | 568 | 0.020 |
Why?
|
Oximes | 1 | 2004 | 6 | 0.020 |
Why?
|
Hispanic Americans | 1 | 2011 | 904 | 0.020 |
Why?
|
Smoking | 1 | 2007 | 427 | 0.010 |
Why?
|
Piperidines | 1 | 2004 | 125 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 440 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 148 | 0.010 |
Why?
|